the aid library

LIST OPTIONS

Filter

3487

Download (945)

View PDF (1938)

Guidance on oral pre-exposure prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstratio

World Health Organization (2012)

Download (595)

View PDF (788)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (382)

View PDF (425)

Checklist for assessing quality of healthcare - Hospitals

Kenya Ministry of Health (2021) C1

Kenya Quality Model for Health - Hospitals

Download (988)

View PDF (1304)

Ghana National Health Insurance Scheme Improving Financial Sustainability Based on Expenditure Review

Huihui Wang, Nathaniel Otoo, and Lydia Dsane-Selby World Bank Group (2017) C1

Download (615)

View PDF (800)

Relevance of CBR and Inclusive Development in Post 2015 Agenda

Thomas, M. and Ninomiya, A. CBR Asia-Pacific Network (2015) C1

Download (584)

View PDF (864)

Guidelines on second-and third-line medicines and type of insulin for the control of blood glucose levels in non-pregnant adults with diabetes mellitus

World Health Organization WHO (2018) C_WHO

The new guidelines provide public health guidance on pharmacological agents for managing hyperglycaemia in type 1 and type 2 diabetes for use in primary health-care in low-resource settings. These guidelines update the recommendations for managing hyperglycaemia in the WHO Package of Essential NCD I... more

Download (334)

View PDF (459)

Redefining the Antibiotic Stewardship Team

Centers for Disease Control and Prevention CDC, American Nurses Association ANA (2017) C_CDC

Recommendations from the American Nurses Association/Centers for Disease Control and Prevention Workgroup on the Role of Registered Nurses in Hospital Antibiotic Stewardship Practices

Download (403)

View PDF (397)

The Core Elements of Outpatient Antibiotic Stewardship

Centers for Disease Control and Prevention CDC (2019) C_CDC

The Core Elements of Outpatient Antibiotic Stewardship provides a framework for antibiotic stewardship for outpatient clinicians and facilities that routinely provide antibiotic treatment. This report augments existing guidance for other clinical settings. In 2014 and 2015, respectively, CDC release... more

Download (381)

View PDF (648)

Preventing and mitigating COVID-19 at work

World Health Organization WHO (2021) C_WHO

Workplaces outside of healthcare facilities can be also settings for transmission of COVID-19. Outbreaks of COVID-19 has been reported in various types of workplaces and job categories. All workers should be protected from acquiring COVID-19 because of their work. The prevention of COVID-19 in ... more

Download (411)

View PDF (586)

AMR-SORT IT 2021 annual report

World Health Organization WHO; Special Programme for TDR (2022) C_WHO

During the first two years of the project (2019–2020), through a ‘One Health’ approach, comprehensive engagement was established with AMR coordinating committees, WHO regional and country offices and SORT IT partners in Asia, Africa, Europe and the Americas. Thirty-seven research studies were ... more

Download (399)

View PDF (584)

A safe operating space for humanity

Rockström, J.; Steffen, W., Noone, K., et al. (2009) C1

Identifying and quantifying planetary boundaries that must not be transgressed could help prevent human activities from causing unacceptable environmental changes. nature Vol 461|24 September 2009

External Link

Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever -Revised and expanded edition

World Health Organization WHO Regional Office for South-East Asia WHO Regional Office for South-East Asia (2011) CC

Revised and expanded version of the Guidelines

Download (358)

View PDF (507)

Tracking official development assistance for reproductive health in conflict-affected countries: 2002—2011

Patel P.; Dahab M.; Tanabe M. et al. BJOG An International Journal of Obstetics and Gynaecology (2016) CC

To provide information on trends on official development assistance (ODA) disbursement patterns for reproductive health activities in 18 conflict-affected countries

Download (411)

View PDF (473)

MAKING IT HAPPEN: Examples of good practice in SPECIAL NEEDS EDUCATION & COMMUNITY-BASED PROGRAMMES

United Nations Educational, Scientific and Cultural Organization (UNESCO) (1993)

This monograph presents 12 reports of successful programs serving children with special needs in various nations. The program locations and the program report titles and authors are as follows: (1) Austria: "Integration Models for Elementary and Secondary Schools in Austria" (Volker Rutte)... more

External Link

Drug-resistant tuberculosis in Central Mozambique: the role of a rapid genotypic susceptibility testing

Evangelina IN, Inês T, Miguelhete L et al (2016) CC

This study consists of a descriptive analysis of M. tuberculosis isolates from Beira Central Hospital, Mozambique, during 2014–2015, being the first report of a genotypic testing used to provide information about second line drug resistance in Mozambique. BMC Infectious Diseases (2016) 16:423 DO... more